• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.

One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes.

Details
Publisher DOI
10.4244/EIJ-D-23-00658
PubMed ID
38776146
Abstract
BACKGROUND

A short dual antiplatelet therapy (DAPT) duration has been proposed for patients at high bleeding risk (HBR) undergoing drug-eluting coronary stent (DES) implantation. Whether this strategy is safe and effective after a non-ST-segment elevation acute coronary syndrome (NSTE-ACS) remains uncertain.

AIMS

We aimed to compare the impact of 1-month versus 3-month DAPT on clinical outcomes after DES implantation among HBR patients with or without NSTE-ACS.

METHODS

This is a prespecified analysis from the XIENCE Short DAPT programme involving three prospective, international, single-arm studies evaluating the safety and efficacy of 1-month (XIENCE 28 USA and Global) or 3-month (XIENCE 90) DAPT among HBR patients after implantation of a cobalt-chromium everolimus-eluting stent. Ischaemic and bleeding outcomes associated with 1- versus 3-month DAPT were assessed according to clinical presentation using propensity score stratification.

RESULTS

Of 3,364 HBR patients (1,392 on 1-month DAPT and 1,972 on 3-month DAPT), 1,164 (34.6%) underwent DES implantation for NSTE-ACS. At 12 months, the risk of the primary endpoint of death or myocardial infarction was similar between 1- and 3-month DAPT in patients with (hazard ratio [HR] 1.09, 95% confidence interval [CI]: 0.71-1.65) and without NSTE-ACS (HR 0.88, 95% CI: 0.63-1.23; p-interaction=0.34). The key secondary endpoint of Bleeding Academic Research Consortium (BARC) Type 2-5 bleeding was consistently reduced in both NSTE-ACS (HR 0.57, 95% CI: 0.37-0.88) and stable patients (HR 0.84, 95% CI: 0.61-1.15; p-interaction=0.15) with 1-month DAPT.

CONCLUSIONS

Among HBR patients undergoing implantation of an everolimus-eluting stent, 1-month, compared to 3-month DAPT, was associated with similar ischaemic risk and reduced bleeding at 1 year, irrespective of clinical presentation.
Date Issued
2024-05-20
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Author(s)
Cao, Davide
Vranckx, Pascal
Valgimigli, Marco  
Universitätsklinik für Kardiologie  
Sartori, Samantha
Angiolillo, Dominick J
Bangalore, Sripal
Bhatt, Deepak L
Feng, Yihan
Ge, Junbo
Hermiller, James
Makkar, Raj R
Neumann, Franz-Josef
Saito, Shigeru
Picon, Hector
Toelg, Ralph
Maksoud, Aziz
Chehab, Bassem M
Choi, James W
Campo, Gianluca
De la Torre Hernandez, José M
Krucoff, Mitchell W
Kunadian, Vijay
Sardella, Gennaro
Spirito, Alessandro
Thiele, Holger
Varenne, Olivier
Vogel, Birgit
Zhou, Yujie
Windecker, Stephan  
Universitätsklinik für Kardiologie  
Mehran, Roxana
Additional Credits
Universitätsklinik für Kardiologie  
Journal
EuroIntervention
Publisher
Europa Digital & Publishing
ISSN
1969-6213
Access(Rights)
metadata.only
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 24f0a9 [ 4.09. 8:55]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify